Thursday, FEB. 20, 2025 (Healthday News)-Patients with irritable bowel syndrome (IBS) on an immunoglobulin (IG) G-guided elimination diet are more like a 30 percent or greater reduction in abdominal pain intensity (API), according to a Study Published Online Jan. 31 In Gastroenterology.
PRASHANT SINGH, MBBS, FROM MICHIGAN MEDICINE IN ANN ARBOR, AND COLLECTIONS DRIVED A RANDOMIZED, DUBLE-BLIND TRIAL INVOLRING PATS WITH IBS FROM EIGHT CENTERS TO EXEMINE THE EFFICACY OF AN ELIMINATION DIET UTILIZING A Novel IBS-SEPECIFIC IGG ASSAY. The Total of 238 Patients Positive for One or more foods on an 18-food Igg Assay and with an average Daily Api Score Between 3 and 7.5 on an 11-Point Scale During a Two-Week Run-In Period Were Randomly Assigned to Eight Weeks OF EITHER AN EXPERIMENTAL ANTIBODY-GUIDED diet or sham diet. The Modified Intenti-to-Treat Analysis Included 223 Patients.
The Researchers Found That Significant More Patients in the Experimental Diet Group That the Sham Diet Group Met the Primary Outcome of A ≥30 Percent Decrease in Api for Two or More of the Last Four Weks of the Treatment Period (59.6 versus 42.1 Percent). Compred with the Sham Group, the Significant Higher Prortion of Patients in the Experimental Group with Constipation-Predominant IBS (IBS-C) and IBS with Mixed Bowel Habits (IBS-M) Met the Primary End Point (67.1 versus 35.8 Percent and 66 versus 29.5 Percent, respective).
“Given Our Promising Results, A Larger Study, Possibly Focusing on IBS-C and IBS-M Patients, Should Be Considered,” The Authors Write.
Several Authors Disclosed Ties to Biotechnology and Pharmaceutical Companies, Including Biomerica, Which Funded the Study.
Abstract/Full Text (Subscription or Payment May Be Required)
Copyright © 2025 Healthday. All Rights Reserved.
